ADAP vs. IVVD, PSTX, SOPH, STRO, CADL, JSPR, GLUE, MGX, BDTX, and CRBU
Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Invivyd (IVVD), Poseida Therapeutics (PSTX), SOPHiA GENETICS (SOPH), Sutro Biopharma (STRO), Candel Therapeutics (CADL), Jasper Therapeutics (JSPR), Monte Rosa Therapeutics (GLUE), Metagenomi (MGX), Black Diamond Therapeutics (BDTX), and Caribou Biosciences (CRBU). These companies are all part of the "biological products, except diagnostic" industry.
Adaptimmune Therapeutics (NASDAQ:ADAP) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends.
31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 12.4% of Adaptimmune Therapeutics shares are owned by company insiders. Comparatively, 17.9% of Invivyd shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Adaptimmune Therapeutics has a beta of 2.44, suggesting that its stock price is 144% more volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.
Adaptimmune Therapeutics has higher revenue and earnings than Invivyd. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.
In the previous week, Invivyd had 9 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 16 mentions for Invivyd and 7 mentions for Adaptimmune Therapeutics. Invivyd's average media sentiment score of 0.35 beat Adaptimmune Therapeutics' score of 0.24 indicating that Invivyd is being referred to more favorably in the news media.
Adaptimmune Therapeutics received 300 more outperform votes than Invivyd when rated by MarketBeat users. However, 63.64% of users gave Invivyd an outperform vote while only 62.53% of users gave Adaptimmune Therapeutics an outperform vote.
Invivyd has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -188.90%. Invivyd's return on equity of -93.58% beat Adaptimmune Therapeutics' return on equity.
Adaptimmune Therapeutics currently has a consensus target price of $2.50, indicating a potential upside of 108.33%. Invivyd has a consensus target price of $11.33, indicating a potential upside of 362.59%. Given Invivyd's stronger consensus rating and higher possible upside, analysts plainly believe Invivyd is more favorable than Adaptimmune Therapeutics.
Summary
Invivyd beats Adaptimmune Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Adaptimmune Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptimmune Therapeutics Competitors List
Related Companies and Tools
